Valuation: Zai Lab Limited

Market Cap 2.71B 21.26B 2.35B 2.22B 2.01B 3.77B 260B 3.8B 26.47B 10.2B 132B 10.18B 9.95B 419B P/E 2026 *
-10.9x
P/E 2027 * -10.9x
Enterprise Value 2.25B 17.67B 1.95B 1.84B 1.67B 3.13B 216B 3.16B 22B 8.48B 110B 8.46B 8.27B 348B EV / Sales 2026 *
5.16x
EV / Sales 2027 * 4.22x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week-8.67%
Current month-4.24%
1 month-7.96%
3 months+43.85%
6 months+32.59%
Current year+38.90%
1 week 18.59
Extreme 18.59
20.38
1 month 18.59
Extreme 18.59
21.42
Current year 12.31
Extreme 12.31
21.42
1 year 12.31
Extreme 12.31
27.28
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
106.6
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-8.67% - - 2.71B
+2.02%-1.70%+39.11%-4.31% 78.04B
+1.17%+3.62%+508.92%+28.90% 57.48B
+2.68%-1.68%-17.44%-36.27% 57.4B
+0.35%-1.87%-11.03%+27.74% 48.81B
+2.38%+0.10%+2.43%+155.34% 45.5B
+0.20%+2.39%+51.81%-15.11% 32.08B
+0.73%-1.63%+47.19%+92.77% 24.62B
+3.53%-5.42%-1.02%+170.53% 20.77B
+2.24%-0.40%+64.18%+100.09% 15.75B
Average +1.54%-3.64%+76.02%+57.74% 42.27B
Weighted average by Cap. +1.67%-3.44%+91.18%+38.33%

Financials

2026 *2027 *
Net sales 436M 3.42B 378M 357M 324M 607M 41.83B 612M 4.26B 1.64B 21.22B 1.64B 1.6B 67.47B 552M 4.33B 478M 451M 410M 768M 52.92B 774M 5.39B 2.08B 26.85B 2.07B 2.03B 85.35B
Net income -241M -1.89B -209M -197M -179M -335M -23.07B -337M -2.35B -906M -11.7B -904M -884M -37.2B -211M -1.66B -183M -173M -157M -294M -20.23B -296M -2.06B -794M -10.26B -793M -775M -32.63B
Net Debt -458M -3.59B -397M -374M -340M -637M -43.86B -641M -4.47B -1.72B -22.25B -1.72B -1.68B -70.74B -381M -2.99B -330M -311M -283M -530M -36.5B -534M -3.72B -1.43B -18.52B -1.43B -1.4B -58.87B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
14/09/26 HK$18.96 +0.11% 4,856,200
11/09/26 HK$18.94 +0.91% 12,212,468
10/09/26 HK$18.77 -6.15% 10,011,700
09/09/26 HK$20.00 0.00% 4,651,400
08/09/26 HK$20.00 -0.40% 2,990,900
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.14USD
Average target price
33.14USD
Spread / Average Target
+37.28%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!